JPS6118526B2 - - Google Patents

Info

Publication number: JPS6118526B2
Authority: JP; Japan
Prior art keywords: ara; tmp; drug; dna virus; therapeutic agent
Prior art date: 1979-04-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

JP5117979A

Other languages

English (en)

Japanese (ja)

Other versions

JPS55149213A (en

Inventor

Haruhiko Machida

Minero Saneyoshi

Hiroshi Yoshino

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Yamasa Shoyu KK

Original Assignee

Yamasa Shoyu KK

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1979-04-24

Filing date

1979-04-24

Publication date

1986-05-13

1979-04-24 Application filed by Yamasa Shoyu KK filed Critical Yamasa Shoyu KK

1979-04-24 Priority to JP5117979A priority Critical patent/JPS55149213A/ja

1980-11-20 Publication of JPS55149213A publication Critical patent/JPS55149213A/ja

1986-05-13 Publication of JPS6118526B2 publication Critical patent/JPS6118526B2/ja

Status Granted legal-status Critical Current

Links

239000003814 drug Substances 0.000 claims description 14
229940079593 drug Drugs 0.000 claims description 9
239000003889 eye drop Substances 0.000 claims description 8
239000000243 solution Substances 0.000 claims description 8
229940012356 eye drops Drugs 0.000 claims description 7
150000003839 salts Chemical class 0.000 claims description 7
208000004449 DNA Virus Infections Diseases 0.000 claims description 6
239000007864 aqueous solution Substances 0.000 claims description 6
239000007924 injection Substances 0.000 claims description 6
238000002347 injection Methods 0.000 claims description 6
229940124597 therapeutic agent Drugs 0.000 claims description 5
230000009385 viral infection Effects 0.000 claims description 4
208000036142 Viral infection Diseases 0.000 claims description 3
239000002075 main ingredient Substances 0.000 claims 1
IGWHDMPTQKSDTL-JBPTWFHOSA-N [(2r,3s,4s)-3,4-dihydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl dihydrogen phosphate Chemical compound O=C1NC(=O)C(C)=CN1C1[C@@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IGWHDMPTQKSDTL-JBPTWFHOSA-N 0.000 description 16
241000699670 Mus sp. Species 0.000 description 8
241000700605 Viruses Species 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 6
DWRXFEITVBNRMK-JAGXHNFQSA-N Spongothymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 DWRXFEITVBNRMK-JAGXHNFQSA-N 0.000 description 6
230000000840 anti-viral effect Effects 0.000 description 6
210000004027 cell Anatomy 0.000 description 6
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 5
238000009472 formulation Methods 0.000 description 5
239000000203 mixture Substances 0.000 description 5
208000005100 Herpetic Keratitis Diseases 0.000 description 4
206010073938 Ophthalmic herpes simplex Diseases 0.000 description 4
OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
201000010884 herpes simplex virus keratitis Diseases 0.000 description 4
241001529453 unidentified herpesvirus Species 0.000 description 4
-1 1-β- D-arabinofuranosyl-thymine-triphosphate Chemical compound 0.000 description 3
230000006820 DNA synthesis Effects 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000008187 granular material Substances 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
238000000034 method Methods 0.000 description 3
239000008213 purified water Substances 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
206010020565 Hyperaemia Diseases 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
208000025865 Ulcer Diseases 0.000 description 2
210000004102 animal cell Anatomy 0.000 description 2
239000003443 antiviral agent Substances 0.000 description 2
239000002585 base Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000011575 calcium Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
239000006071 cream Substances 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
208000030533 eye disease Diseases 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
239000008309 hydrophilic cream Substances 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
239000007788 liquid Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
210000004877 mucosa Anatomy 0.000 description 2
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
239000002674 ointment Substances 0.000 description 2
239000003883 ointment base Substances 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
230000000306 recurrent effect Effects 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
231100000397 ulcer Toxicity 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
230000004543 DNA replication Effects 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
208000007514 Herpes zoster Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
206010043275 Teratogenicity Diseases 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
238000011047 acute toxicity test Methods 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
230000032683 aging Effects 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
OIRDTQYFTABQOQ-UHFFFAOYSA-N ara-adenosine Natural products Nc1ncnc2n(cnc12)C1OC(CO)C(O)C1O OIRDTQYFTABQOQ-UHFFFAOYSA-N 0.000 description 1
239000007640 basal medium Substances 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
210000003560 epithelium corneal Anatomy 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229940068918 polyethylene glycol 400 Drugs 0.000 description 1
229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
231100000211 teratogenicity Toxicity 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
230000005727 virus proliferation Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000003871 white petrolatum Substances 0.000 description 1

Landscapes

Saccharide Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP5117979A 1979-04-24 1979-04-24 Remedy of dna for viral disease Granted JPS55149213A (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP5117979A JPS55149213A (en)	1979-04-24	1979-04-24	Remedy of dna for viral disease

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP5117979A JPS55149213A (en)	1979-04-24	1979-04-24	Remedy of dna for viral disease

Publications (2)

Publication Number	Publication Date
JPS55149213A JPS55149213A (en)	1980-11-20
JPS6118526B2 true JPS6118526B2 (fr)	1986-05-13

Family

ID=12879605

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP5117979A Granted JPS55149213A (en)	1979-04-24	1979-04-24	Remedy of dna for viral disease

Country Status (1)

Country	Link
JP (1)	JPS55149213A (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1308352C (fr) *	1986-08-15	1992-10-06	James V. Peck	Compositions comprenant des azacyclohexanes substituees par des composes 1-oxohydrocarbyles
US5073544A (en) *	1986-08-15	1991-12-17	Whitby, Inc.	Transdermal compositions of 1-oxohydrocarbyl-substituted azacyclohexanes

1979
- 1979-04-24 JP JP5117979A patent/JPS55149213A/ja active Granted

Also Published As

Publication number	Publication date
JPS55149213A (en)	1980-11-20

Publication	Publication Date	Title
DE69834658T2 (de)	2007-05-03	Verwendung von aminothiolverbindungen zur behandlung von nerven- und nieren-erkrankungen und der arzneimitteltoxizität
RU2268732C2 (ru)	2006-01-27	Способы лечения митохондриальных нарушений
KR0125931B1 (ko)	1997-12-26	기관내 허혈병의 치료용 조성물
US4879277A (en)	1989-11-07	Antiviral compositions and methods
Maudgal et al.	1980	(E)-5-(2-bromovinyl)-2'-Deoxyuridine in the treatment of experimental herpes simplex keratitis
EP0631783A1 (fr)	1995-01-04	Combinaisons antivirales de 2',3'-didéoxy-ribonucléosides avec des dérivés 5-substitués du 6-benzyl-1-éthoxyméthyl-uracile
US6632445B2 (en)	2003-10-14	Unit dosage forms for the treatment of herpes simplex
EP0296620A2 (fr)	1988-12-28	Utilisation des sels d'acide n-acétylneuraminique pour la fabrication d'un médicament pour décongester la membrane pituitaire
EP0711134B1 (fr)	2000-09-06	Medicament de protection contre les alterations neurologiques
KR19980703420A (ko)	1998-11-05	지도부딘, 1592ｕ89 및 3ｔｃ 또는 ｆｔｃ의 상승적 배합물
US5491135A (en)	1996-02-13	Compositions of N-(phosphonoacetyl)-L-aspartic acid and methods of their use as broad spectrum antivirals
La Lau et al.	1982	Acyclovir and trifluorothymidine in herpetic keratitis: a multicentre trial
EP0479336A1 (fr)	1992-04-08	Composés antiviraux
AU638251B2 (en)	1993-06-24	Method for protection from azt side effects and toxicity
EP0660710A1 (fr)	1995-07-05	Compositions d'acide n-(phosphonoacetyle)-l-aspartique (pala) et procedes d'utilisation de ces dernieres en tant que compositions antivirales a large spectre
AU3200699A (en)	1999-10-18	Azt derivatives exhibiting spermicidal and anti-viral activity
CA1092510A (fr)	1980-12-30	No translation available
US5116600A (en)	1992-05-26	Composition and method for inhibiting inflammation caused by non-parenteral administration of 5-fluorouracil type compounds
JP4232866B2 (ja)	2009-03-04	細胞障害抑制剤
EP0101441B1 (fr)	1987-01-14	Compositions anti-virales
CA2193396A1 (fr)	1995-12-28	Composition pharmaceutique pour prevenir et/ou traiter des infections virales, ainsi qu'eventuellement des inflammations, et utilisation de cette composition
Cheng et al.	1999	Intravitreal pharmacokinetics in rabbits of the foscarnet lipid prodrug: 1-O-octadecyl-sn-glycerol-3-phosphonoformate (ODG-PFA)
JP2714678B2 (ja)	1998-02-16	虚血性臓器障害予防・治療剤
US4044122A (en)	1977-08-23	Method of treating herpes virus hominis infections
JPS6310685B2 (fr)	1988-03-08